The Centre amended the Drugs Rules, 1945 to bring cell or stem cell-derived products, gene therapeutic products and xenografts under the Centrally License Approving Authority (CLAA) framework.
CLAA means joint Central and State licensing; it already covered vaccines, large volume parenterals (IV fluids above 100 ml) and r-DNA medicines.
The aim is uniform standards and closer scrutiny for complex therapies such as CAR-T cells, gene editing and animal-tissue heart valves.
Parent law on import, manufacture, sale and distribution of drugs; creates the Drugs Technical Advisory Board (Section 5) and the Drugs Consultative Committee, which advises on uniform administration across States
Rules under the 1940 Act, amended here; State drug controllers issue manufacturing and sale licences under them, with CLAA products needing Central approval as well
Already classify cell and stem cell-derived products and gene therapeutic products as 'new drugs', so their approval and trials sit with CDSCO; the 2026 amendment adds joint licensing of their manufacture
Released November 2019 by ICMR with the Department of Biotechnology; ethical and scientific norms for gene therapy trials
National drug regulator under the Directorate General of Health Services, Ministry of Health and Family Welfare; acts as the Central License Approving Authority, approves new drugs, clinical trials and imports
Re-engineer a patient's own T cells to attack cancer
Key: Cell-derived product used for blood cancers such as leukaemias and lymphomas
India's first indigenous CAR-T therapy
Key: Developed by ImmunoACT (IIT Bombay spin-off) with Tata Memorial Centre; CDSCO approval October 2023; launched by President Droupadi Murmu at IIT Bombay on 4 April 2024
Replace or edit faulty genes
Key: Used for genetic disorders and several cancers
Transplant animal-derived tissue into humans (xenotransplantation)
Key: e.g. glutaraldehyde-fixed porcine or bovine bioprosthetic heart valves, in use for over 50 years
GS Paper 3 > Science & Technology > Biotechnology; GS Paper 2 > Health
General Awareness > Science & Health
With reference to the use of nanotechnology in health sector, which of the following statements is/are correct? 1. Targeted drug delivery is made possible by nanotechnology. 2. Nanotechnology can largely contribute to gene therapy. Which of the statements given above is/are correct?
Answer: Both 1 and 2
Centrally License Approving Authority: joint Centre-State licensing for critical drug categories
Animal tissue transplanted into a human, e.g. a pig heart valve
Chimeric antigen receptor T-cell therapy for blood cancers